MARSEILLE, France - Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA), a clinical-stage biotechnology company with a market capitalization of $182 million, has announced new preclinical ...

This milestone strengthens the company's FDA Orphan Drug Application and positions Exousia Pro to become a leader in innovative cancer treatments. Nearly 90% of glioblastoma preclinical studies ...

The publication sheds light on the selective targeting of ROS1 drug-resistant mutations by zidesamtinib, particularly the common G2032R mutation. Preclinical studies ... insights about the company’s ...

Accomplished physician-scientist brings more than 30 years of industry leadership experience and CNS drug development expertise. SEATTLE, April 29, 2025 /PRNewswire/ -- Transneural Therapeutics, Inc. ...

Javascript is required for you to be able to read premium content. Please enable it in your browser settings.

Background IBD is a chronic inflammatory condition driven by complex genetic and immune interactions, yet preclinical models often fail to fully recapitulate all aspects of the human disease. A ...

Our team of proven drug developers is advancing an antibody-drug conjugate with our proprietary linker technology, a T-cell engager with wide therapeutic window, and a multi-functional checkpoint ...

Zymeworks presents six posters at AACR highlighting advancements in antibody-drug conjugates ... of six posters with new preclinical data from its preclinical, development-stage, and clinical ...

announced robust preclinical data supporting the mechanism of action for its leading drug candidate, micvotabart pelidotin (MICVO), and its continued clinical development. According to ...

The development of therapeutic antibodies ... This framework illustrates the flexibility of mouse model humanization for drug-specific preclinical assessment and highlights the potential in across ...